This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Ironwood (IRWD) Q4 Loss Narrower than Expected; Sales Top
by Zacks Equity Research
Ironwood Pharmaceuticals, Inc. (IRWD) reported an adjusted loss of 12 cents per share in the fourth quarter of 2016, narrower than the Zacks Consensus Estimate of a loss of 23 cents but slightly wider than the year-ago loss of 11 cents.
Valeant's (VRX) Plaque Psoriasis Drug Approved in the U.S.
by Zacks Equity Research
Valeant Pharmaceuticals (VRX) recently announced that the the FDA has approved its Biologic License Application (BLA) for Siliq (brodalumab) injection the treatment of moderate-to-severe plaque psoriasis in adult patients.
Pharma Stock Roundup: Merck's Alzheimer's Study Halted, Allergan to Buy ZELTIQ
by Arpita Dutt
The main news this week was an update from Merck (MRK) regarding its Alzheimer's disease drug.
Alzheimer's Market Suffers Yet Another Blow with Merck Drug Setback
by Arpita Dutt
Merck's (MRK) news represents the latest setback in the pharma and biotech sector's quest to find a treatment for Alzheimer's.
Lilly's Olumiant Gets Marketing Authorization in Europe
by Zacks Equity Research
Eli Lilly and Company (LLY) along with its partner Incyte Corporation (INCY) announced that the European Commission has granted marketing authorization to once-daily baricitinib in Europe.
Pharma Stock Roundup: Allergan, GSK Top 4Q Earnings, Praluent Breather for Sanofi
by Arpita Dutt
Key highlights this week include earnings results from Allergan (AGN) and Glaxo, Sanofi's update regarding Praluent and Teva's ongoing woes.
Agilent (A) Announces Expanded Use of Diagnostic Assay (revised)
by Zacks Equity Research
Agilent Technologies (A) recently announced the expanded use of its diagnostic assay, Dako PD-L1 IHC 22C3 pharmDx.
AstraZeneca (AZN) Beats on Q4 Earnings but Misses on Sales
by Zacks Equity Research
AstraZeneca PLC (AZN) reported fourth-quarter 2016 core earnings of $1.21 per American Depositary Share, which comfortably beat the Zacks Consensus Estimate of 51 cents. Core earnings also rose 9% year over year.
Agilent (A) Announces Expanded Use of Diagnostic Assay
by Zacks Equity Research
Agilent Technologies (A) recently announced the expanded use of its diagnostic assay, Dako PD-L1 IHC 28-8 22C3 pharmDx. This marks the company's effort to expand in the growing companion diagnostics market.
Allergan (AGN) Avycaz Label to Include New Phase III Data
by Zacks Equity Research
Allergan plc (AGN) announced that its supplemental new drug application (sNDA) for antibiotic Avycaz has been approved by the FDA. Allergan is looking to include new data from two phase III trials, RECAPTURE and REPRISE, in the drug???s label.
Ironwood/Astellas Report Positive Phase III Data on Linzess
by Zacks Equity Research
Ironwood (IRWD) and partner Astellas reported positive top-line data from a phase III study on Linzess in adults with chronic constipation.
AstraZeneca's Symbicort Granted Pediatric Exclusivity by FDA
by Zacks Equity Research
AstraZeneca (AZN) announced that the FDA has granted six months of pediatric exclusivity to its Symbicort inhalation aerosol.
Ironwood-Allergan Linzess Gets FDA Approval in Lower Dose
by Zacks Equity Research
Ironwood Pharmaceuticals, Inc. (IRWD) and partner Allergan plc (AGN) announced that the FDA has approved a lower dose strength of Linzess (linaclotide) ??? 72 mcg ??? for the treatment of adult patients with chronic idiopathic constipation (CIC).
Microsoft (MSFT) Beats on Q2 Earnings, Revenue Estimates
by Zacks Equity Research
Microsoft Corporation (MSFT) reported second-quarter fiscal 2017 earnings of 83 cents per share, which comfortably surpassed the Zacks Consensus Estimate of 79 cents.
Pharma Stock Roundup: J&J to Buy Actelion, Bristol-Myers' 4Q Results Disappoint
by Arpita Dutt
Key highlights this week include earnings reports from companies like Bristol-Myers (BMY) as well as the J&J-Actelion deal.
AstraZeneca Offers Update on Immuno-Oncology Program
by Zacks Equity Research
AstraZeneca (AZN) provided an update on its late-stage immuno-oncology program for first-line NSCLC.
Can AstraZeneca (AZN) Be a Solid Choice for Value Investors?
by Zacks Equity Research
Let's see if AstraZeneca (AZN) stock is a good choice for value-oriented investors right now from multiple angles.
The FDA Approved Fewer Drugs in 2016: Here's Why
by Arpita Dutt
Was there any specific reason for the significantly lower number of drug approvals in 2016 compared to 2015?
Pharma Stock Roundup: PCSK9 Inhibitor Praluent in News, Allergan's Preliminary 2017 View
by Arpita Dutt
Key highlights this week include a court injunction blocking sales of PCSK9 inhibitor Praluent and preliminary guidance from Allergan (AGN).
Pharma Stock Roundup: Cempra Plunges to 52-Week Low, Shire Drug Label Expanded
by Arpita Dutt
Key highlights this week include complete response letters from the FDA for a couple of companies with Cempra (CEMP) plunging to a 52-week low.
Pfizer Ibrance sNDA Accepted by FDA under Priority Review
by Zacks Equity Research
Pfizer Inc.'s (PFE) supplemental new drug application (sNDA) to convert accelerated approval for its breast cancer drug, Ibrance, to regular approval was accepted by the FDA under priority review.
Clovis Scales 52-Week High on Early FDA Nod for Rubraca
by Zacks Equity Research
Shares of Clovis Oncology (CLVS) touched a 52-week high after the company gained accelerated FDA nod for its advanced ovarian cancer drug, Rubraca.
Ionis (IONS) Receives Milestone Payment from AstraZeneca
by Zacks Equity Research
Ionis (IONS) received $28 million from AstraZeneca (AZN) following the completion of IND-supporting studies and licensing of IONIS-KRAS-2.5.
Alexion Slips to 52-Week Low as CEO, CFO Quit amid Probe
by Zacks Equity Research
Alexion's (ALXN) shares plunged after the company's board of directors announced new leadership appointments.
Biogen Presents Positive Early Data from Alzheimer's Study
by Zacks Equity Research
Last week, Biogen Inc. (BIIB) presented positive data from a phase I study (PRIME) on its anti-amyloid treatments in development, aducanumab, at the Clinical Trials on Alzheimer's Disease (CTAD) meeting in San Diego.